J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

BioSpace presents 25 noteworthy biopharma startups in ’25; analysts forecast stronger M&A as the J.P. Morgan Healthcare Conference kicks off next week; GLP-1s continue to expand their reach as Novo, ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...